Pathogenesis and Management of Venous Thromboembolism in Cancer Patients

  • Michael B. StreiffEmail author
Part of the Cancer Drug Discovery and Development book series (CDD&D)


One hundred and forty one years have passed since Armand Trousseau’s initial observation that venous thromboembolism (VTE) is a common manifestation of an underlying malignancy (1). Despite widespread recognition of this association and the availability of a multiple options for prevention and treatment of venous thrombosis, VTE remains a common cause of morbidity and mortality in cancer patients. The purpose of this chapter will be to review: (1) The epidemiology of VTE in cancer patients, (2) The pathogenesis of cancer-related thrombosis, (3) The prevention and treatment of VTE in the cancer patient, and (4) Special topics in VTE management including management of recurrent VTE and heparin-induced thrombocytopenia.


Venous thromboembolism Deep venous thrombosis Pulmonary embolism Prophylaxis Treatment 


  1. 1.
    Trousseau A. Phlegmasia alba dolens. In: Trouuseau A, editor. Clinique Medicale de l’Hotel-Dieu de Paris. Paris: Balliere, 1865: 654–712.Google Scholar
  2. 2.
    Heit JA, Silverstein MD, Mohr DN. et al. 2000; Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 160:(6)809–815.PubMedGoogle Scholar
  3. 3.
    Blom JW, Doggen CJ, Osanto S, Rosendaal FR. 2005; Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 293:(6)715–722.PubMedGoogle Scholar
  4. 4.
    Deitcher SR. 2003; Cancer and thrombosis: mechanisms and treatment. J Thromb Thrombolysis. 16:(1–2)21–31.PubMedGoogle Scholar
  5. 5.
    Levitan N, Dowlati A, Remick SC. et al. 1999; Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 78:(5)285–291.Google Scholar
  6. 6.
    Blom JW, Vanderschoot JP, Oostindier MJ. et al. 2006; Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost. 4:(3)529–535.PubMedGoogle Scholar
  7. 7.
    Stein PD, Beemath A, Meyers FA. et al. 2006; Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med. 119:(1)60–68.PubMedGoogle Scholar
  8. 8.
    Khorana AA, Francis CW, Culakova E. et al. 2006; Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol. 24:(3)484–490.PubMedGoogle Scholar
  9. 9.
    Chew HK, Wun T, Harvey D. et al. 2006; Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 166:(4)458–464.PubMedGoogle Scholar
  10. 10.
    Ogren M, Bergqvist D, Wahlander K. et al. 2006; Trousseau’s syndrome - what is the evidence? A population-based autopsy study. Thromb Haemost. 95:(3)541–545.PubMedGoogle Scholar
  11. 11.
    Blom JW, Osanto S, Rosendaal FR. 2004; The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost. 2:(10)1760–1765.PubMedGoogle Scholar
  12. 12.
    Baron JA, Gridley G, Weiderpass E. et al. 1998; Venous thromboembolism and cancer. Lancet. 351:(9109)1077–1080.PubMedGoogle Scholar
  13. 13.
    Sorensen HT, Mellemkjaer L, Steffensen FH. et al. 1998; The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med. 338:(17)1169–1173.PubMedGoogle Scholar
  14. 14.
    Piccioli A, Lensing AW, Prins MH. et al. 2004; Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost. 2:(6)884–889.PubMedGoogle Scholar
  15. 15.
    Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. 2000; Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 343:(25)1846–1850.PubMedGoogle Scholar
  16. 16.
    Semeraro N, Colucci M. 1997; Tissue factor in health and disease. Thromb Haemost. 78:(1)759–764.PubMedGoogle Scholar
  17. 17.
    Rong Y, Post DE, Pieper RO. et al. 2005; PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res. 65:(4)1406–1413.PubMedGoogle Scholar
  18. 18.
    Hamada K, Kuratsu J, Saitoh Y. et al. 1996; Expression of tissue factor correlates with grade of malignancy in human glioma. Cancer. 77:(9)1877–1883.PubMedGoogle Scholar
  19. 19.
    Wojtukiewicz MZ, Rucinska M, Zacharski LR. et al. 2001; Localization of blood coagulation factors in situ in pancreatic carcinoma. Thromb Haemost. 86:(6)1416–1420.PubMedGoogle Scholar
  20. 20.
    Gordon SG. 1992; Cancer cell procoagulants and their role in malignant disease. Semin Thromb Hemost. 18:(4)424–433.PubMedGoogle Scholar
  21. 21.
    Hettasch JM, Bandarenko N, Burchette JL. et al. 1996; Tissue transglutaminase expression in human breast cancer. Lab Invest. 75:(5)637–645.PubMedGoogle Scholar
  22. 22.
    Barbui T, Finazzi G, Falanga A. 1998; The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood. 91:(9)3093–3102.PubMedGoogle Scholar
  23. 23.
    Kwaan HC, Keer HN, Radosevich JA. et al. 1991; Components of the plasminogen-plasmin system in human tumor cell lines. Semin Thromb Hemost. 17:(3)175–182.PubMedGoogle Scholar
  24. 24.
    Falanga A, Rickles FR. 1999; Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost. 25:(2)173–182.PubMedGoogle Scholar
  25. 25.
    Nash GF, Walsh DC, Kakkar AK. 2001; The role of the coagulation system in tumour angiogenesis. Lancet Oncol. 2:(10)608–613.PubMedGoogle Scholar
  26. 26.
    Streiff MB, Segal J, Grossman SA. et al. 2004; ABO blood group is a potent risk factor for venous thromboembolism in patients with malignant gliomas. Cancer. 100:(8)1717–1723.PubMedGoogle Scholar
  27. 27.
    Jick H, Porter J. 1978; Thrombophlebitis of the lower extremities and ABO blood type. Arch Intern Med. 138:(10)1566–1567.PubMedGoogle Scholar
  28. 28.
    Talbot S, Wakley EJ, Ryrie D, Langman MJ. 1970; ABO blood groups and venous thromboembolic disease. Lancet. 1:(7659)1257–1259.PubMedGoogle Scholar
  29. 29.
    O’Donnell J, Laffan MA. 2001; The relationship between ABO histo-blood group, factor VIII and von Willebrand factor. Transfus Med. 11:(4)343–351.PubMedGoogle Scholar
  30. 30.
    O’Donnell J, Mumford AD, Manning RA, Laffan M. 2000; Elevation of FVIII: C in venous thromboembolism is persistent and independent of the acute phase response. Thromb Haemost. 83:(1)10–13.PubMedGoogle Scholar
  31. 31.
    Kraaijenhagen RA, in’t Anker PS, Koopman MM. et al. 2000; High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost. 83:(1)5–9.PubMedGoogle Scholar
  32. 32.
    Kyrle PA, Minar E, Hirschl M. et al. 2000; High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med. 343:(7)457–462.PubMedGoogle Scholar
  33. 33.
    Ramacciotti E, Wolosker N, Puech-Leao P. et al. 2003; Prevalence of factor V Leiden, FII G20210A, FXIII Val34Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis. Thromb Res. 109:(4)171–174.PubMedGoogle Scholar
  34. 34.
    Pihusch R, Danzl G, Scholz M. et al. 2002; Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma. Cancer. 94:(12)3120–3126.PubMedGoogle Scholar
  35. 35.
    Abramson N, Costantino JP, Garber JE. et al. 2006; Effect of factor V Leiden and prothrombin G20210 → A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial J Natl Cancer Inst. 98:(13)904–910.PubMedGoogle Scholar
  36. 36.
    Beer JH, Haeberli A, Vogt A. et al. 2002; Coagulation markers predict survival in cancer patients. Thromb Haemost. 88:(5)745–749.PubMedGoogle Scholar
  37. 37.
    White RH, Zhou H, Romano PS. 2003; Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost. 90:(3)446–455.PubMedGoogle Scholar
  38. 38.
    Jhingran A, Eifel PJ. 2000; Perioperative and postoperative complications of intracavitary radiation for FIGO stage I-III carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 46:(5)1177–1183.PubMedGoogle Scholar
  39. 39.
    Holm T, Singnomklao T, Rutqvist LE, 1996; Cedermark B. Adjuvant preoperative radiotherapy in patients with rectal carcinoma. Adverse effects during long-term follow-up of two randomized trials. Cancer. 78:(5)968–976.PubMedGoogle Scholar
  40. 40.
    Silvani A, Salmaggi A, Eoli M. et al. 2003; Venous thromboembolism in malignant glioma patients treated by chemoradiotherapy. Neurol Sci. 24:(4)272.PubMedGoogle Scholar
  41. 41.
    Weitz IC, Israel VK, Waisman JR. et al. 2002; Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation. Thromb Haemost. 88:(2)213–220.PubMedGoogle Scholar
  42. 42.
    Edwards RL, Klaus M, Matthews E. et al. 1990; Heparin abolishes the chemotherapy-induced increase in plasma fibrinopeptide A levels. Am J Med. 89:(1)25–28.PubMedGoogle Scholar
  43. 43.
    Khorana AA, Francis CW, Culakova E, Lyman GH. 2005; Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 104:(12)2822–2829.PubMedGoogle Scholar
  44. 44.
    Levine MN, Gent M, Hirsh J. et al. 1988; The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med. 318:(7)404–407.PubMedGoogle Scholar
  45. 45.
    Goodnough LT, Saito H, Manni A. et al. 1984; Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer. 54:(7)1264–1268.PubMedGoogle Scholar
  46. 46.
    Saphner T, Tormey DC, Gray R. 1991; Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol. 9:(2)286–294.PubMedGoogle Scholar
  47. 47.
    Pritchard KI, Paterson AH, Paul NA. et al. 1996; Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol. 14:(10)2731–2737.PubMedGoogle Scholar
  48. 48.
    Bonneterre J, Buzdar A, Nabholtz JM. et al. 2001; Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer. 92:(9)2247–2258.PubMedGoogle Scholar
  49. 49.
    Weijl NI, Rutten MF, Zwinderman AH. et al. 2000; Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol. 18:(10)2169–2178.PubMedGoogle Scholar
  50. 50.
    Numico G, Garrone O, Dongiovanni V. et al. 2005; Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer. 103:(5)994–999.PubMedGoogle Scholar
  51. 51.
    Jacobson GM, Kamath RS, Smith BJ, Goodheart MJ. 2005; Thromboembolic events in patients treated with definitive chemotherapy and radiation therapy for invasive cervical cancer. Gynecol Oncol. 96:(2)470–474.PubMedGoogle Scholar
  52. 52.
    Priest JR, Ramsay NK, Steinherz PG. et al. 1982; A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia. J Pediatr. 100:(6)984–989.PubMedGoogle Scholar
  53. 53.
    Alberts SR, Bretscher M, Wiltsie JC. et al. 1999; Thrombosis related to the use of L-asparaginase in adults with acute lymphoblastic leukemia: a need to consider coagulation monitoring and clotting factor replacement. Leuk Lymphoma. 32:(5–6)489–496.PubMedGoogle Scholar
  54. 54.
    Priest JR, Ramsay NK, Bennett AJ. et al. 1982; The effect of L-asparaginase on antithrombin, plasminogen, and plasma coagulation during therapy for acute lymphoblastic leukemia. J Pediatr. 100:(6)990–995.PubMedGoogle Scholar
  55. 55.
    Liebman HA, Wada JK, Patch MJ, McGehee W. 1982; Depression of functional and antigenic plasma antithrombin III (AT-III) due to therapy with L-asparaginase. Cancer. 50:(3)451–456.PubMedGoogle Scholar
  56. 56.
    Otten HM, Mathijssen J, ten Cate H. et al. 2004; Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med. 164:(2)190–194.PubMedGoogle Scholar
  57. 57.
    Edwards RL, Klaus M, Matthews E. et al. 1990; Heparin abolishes the chemotherapy-induced increase in plasma fibrinopeptide A levels. Am J Med. 89:(1)25–28.PubMedGoogle Scholar
  58. 58.
    Zangari M, Anaissie E, Barlogie B. et al. 2001; Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 98:(5)1614–1615.PubMedGoogle Scholar
  59. 59.
    Rajkumar SV, Hayman S, Gertz MA. et al. 2002; Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 20:(21)4319–4323.PubMedGoogle Scholar
  60. 60.
    Zangari M, Siegel E, Barlogie B. et al. 2002; Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood. 100:(4)1168–1171.PubMedGoogle Scholar
  61. 61.
    Zangari M, Saghafifar F, Anaissie E. et al. 2002; Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis. 13:(3)187–192.PubMedGoogle Scholar
  62. 62.
    Minnema MC, Fijnheer R, De Groot PG, Lokhorst HM. 2003; Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost. 1:(3)445–449.PubMedGoogle Scholar
  63. 63.
    Baz R, Li L, Kottke-Marchant K. et al. 2005; The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc. 80:(12)1568–1574.PubMedGoogle Scholar
  64. 64.
    Zangari M, Barlogie B, Anaissie E. et al. 2004; Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol. 126:(5)715–721.PubMedGoogle Scholar
  65. 65.
    Ikhlaque N, Seshadri V, Kathula S, Baumann MA. 2006; Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis. Am J Hematol. 81:(6)420–422.PubMedGoogle Scholar
  66. 66.
    Knight R, DeLap RJ, Zeldis JB. 2006; Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med. 354:(19)2079–2080.PubMedGoogle Scholar
  67. 67.
    Kabbinavar F, Hurwitz HI, Fehrenbacher L. et al. 2003; Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 21:(1)60–65.PubMedGoogle Scholar
  68. 68.
    Shah MA, Ilson D, Kelsen DP. 2005; Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy. J Clin Oncol. 23:(11)2574–2576.PubMedGoogle Scholar
  69. 69.
    Kuenen BC, Rosen L, Smit EF. et al. 2002; Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol. 20:(6)1657–1667.PubMedGoogle Scholar
  70. 70.
    Brotman DJ, Girod JP, Posch A. et al. 2006; Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers. Thromb Res. 118:(2)247–252.PubMedGoogle Scholar
  71. 71.
    Verso M, Agnelli G. 2003; Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol. 21:(19)3665–3675.PubMedGoogle Scholar
  72. 72.
    Wun T, Law L, Harvey D. et al. 2003; Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer. 98:(7)1514–1520.PubMedGoogle Scholar
  73. 73.
    Steurer M, Sudmeier I, Stauder R, Gastl G. 2003; Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha. Br J Haematol. 121:(1)101–103.PubMedGoogle Scholar
  74. 74.
    Vansteenkiste J, Pirker R, Massuti B. et al. 2002; Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 94:(16)1211–1220.PubMedGoogle Scholar
  75. 75.
    Galli M, Elice F, Crippa C. et al. 2004; Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma. Haematologica. 89:(9)1141–1142.PubMedGoogle Scholar
  76. 76.
    Feagan BG, Wong CJ, Kirkley A. et al. 2000; Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial. Ann Intern Med. 133:(11)845–854.PubMedGoogle Scholar
  77. 77.
    Smith KJ, Bleyer AJ, Little WC, Sane DC. 2003; The cardiovascular effects of erythropoietin. Cardiovasc Res. 59:(3)538–548.PubMedGoogle Scholar
  78. 77a.
    Bennett CL, Silver SM, Djulbegovic B et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299(8):914–924.PubMedGoogle Scholar
  79. 78.
    Lin A, Ryu J, Harvey D. et al. 2006; Low-dose warfarin does not decrease the rate of thrombosis in patients with cervix and vulvo-vaginal cancer treated with chemotherapy, radiation, and erythropoeitin. Gynecol Oncol. 102:(1)98–102.PubMedGoogle Scholar
  80. 79.
    Bratzler DW, Raskob GE, Murray CK. et al. 1998; Underuse of venous thromboembolism prophylaxis for general surgery patients: physician practices in the community hospital setting. Arch Intern Med. 158:(17)1909–1912.PubMedGoogle Scholar
  81. 80.
    Rahim SA, Panju A, Pai M, Ginsberg J. 2003; Venous thromboembolism prophylaxis in medical inpatients: a retrospective chart review. Thromb Res. 111:(4–5)215–219.PubMedGoogle Scholar
  82. 81.
    Goldhaber SZ, Tapson VF. 2004; A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol. 93:(2)259–262.PubMedGoogle Scholar
  83. 82.
    Kakkar AK, Levine M, Pinedo HM. et al. 2003; Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist. 8:(4)381–388.PubMedGoogle Scholar
  84. 83.
    Stein PD, Beemath A, Meyers FA. et al. 2006; Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med. 119:(1)60–68.PubMedGoogle Scholar
  85. 84.
    Kakkar AK, Williamson RC. 1999; Prevention of venous thromboembolism in cancer patients. Semin Thromb Hemost. 25:(2)239–243.PubMedGoogle Scholar
  86. 85.
    Mismetti P, Laporte S, Darmon JY. et al. 2001; Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg. 88:(7)913–930.PubMedGoogle Scholar
  87. 86.
    . Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. Br J Surg. 1997;84(8):1099–1103.Google Scholar
  88. 87.
    McLeod RS, Geerts WH, Sniderman KW. et al. 2001; Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the Canadian colorectal DVT prophylaxis trial: a randomized, double-blind trial. Ann Surg. 233:(3)438–444.PubMedGoogle Scholar
  89. 88.
    Agnelli G, Bergqvist D, Cohen AT. et al. 2005; Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg. 92:(10)1212–1220.PubMedGoogle Scholar
  90. 89.
    Agnelli G, Bolis G, Capussotti L. et al. 2006; A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg. 243:(1)89–95.PubMedGoogle Scholar
  91. 90.
    Bergqvist D, Agnelli G, Cohen AT. et al. 2002; Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 346:(13)975–980.PubMedGoogle Scholar
  92. 91.
    Rasmussen MS, Jorgensen LN, Wille-Jorgensen P. et al. 2006; Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost. 4:(11)2384–2390.PubMedGoogle Scholar
  93. 92.
    Roderick P, Ferris G, Wilson K. et al. 2005; Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis. Health Technol Assess. 9:(49)iii–x, 1.PubMedGoogle Scholar
  94. 93.
    Geerts WH, Heit JA, Clagett GP. et al. 2001; Prevention of venous thromboembolism. Chest. 119:(1 Suppl)132S–175S.PubMedGoogle Scholar
  95. 94.
    Comerota AJ, Katz ML, White JV. 1992; Why does prophylaxis with external pneumatic compression for deep vein thrombosis fail? Am J Surg. 164:(3)265–268.PubMedGoogle Scholar
  96. 95.
    Cornwell EE, III, Chang D, Velmahos G. et al. 2002; Compliance with sequential compression device prophylaxis in at-risk trauma patients: a prospective analysis. Am Surg. 68:(5)470–473.PubMedGoogle Scholar
  97. 96.
    Agnelli G, Piovella F, Buoncristiani P. et al. 1998; Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med. 339:(2)80–85.PubMedGoogle Scholar
  98. 97.
    Ramos R, Salem BI, De Pawlikowski MP. et al. 1996; The efficacy of pneumatic compression stockings in the prevention of pulmonary embolism after cardiac surgery. Chest. 109:(1)82–85.PubMedGoogle Scholar
  99. 98.
    Kroger K, Weiland D, Ose C. et al. 2006; Risk factors for venous thromboembolic events in cancer patients. Ann Oncol. 17:(2)297–303.PubMedGoogle Scholar
  100. 99.
    Mismetti P, Laporte-Simitsidis S, Tardy B. et al. 2000; Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost. 83:(1)14–19.PubMedGoogle Scholar
  101. 100.
    Samama MM, Cohen AT, Darmon JY. et al. 1999; A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 341:(11)793–800.PubMedGoogle Scholar
  102. 101.
    Lechler E, Schramm W, Flosbach CW. 1996; The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group. Haemostasis. 26:(Suppl 2)49–56.PubMedGoogle Scholar
  103. 102.
    Kleber FX, Witt C, Vogel G. et al. 2003; Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J. 145:(4)614–621.PubMedGoogle Scholar
  104. 103.
    Leizorovicz A, Cohen AT, Turpie AG. et al. 2004; Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 110:(7)874–879.PubMedGoogle Scholar
  105. 104.
    Cohen AT, Davidson BL, Gallus AS. et al. 2006; Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 332:(7537)325–329.PubMedGoogle Scholar
  106. 105.
    Blom JW, Osanto S, Rosendaal FR. 2006; High risk of venous thrombosis in patients with pancreatic cancer: a cohort study of 202 patients. Eur J Cancer. 42:(3)410–414.PubMedGoogle Scholar
  107. 106.
    Monreal M, Raventos A, Lerma R. et al. 1994; Pulmonary embolism in patients with upper extremity DVT associated to venous central lines--a prospective study. Thromb Haemost. 72:(4)548–550.PubMedGoogle Scholar
  108. 107.
    Bern MM, Lokich JJ, Wallach SR. et al. 1990; Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med. 112:(6)423–428.PubMedGoogle Scholar
  109. 108.
    Monreal M, Alastrue A, Rull M. et al. 1996; Upper extremity deep venous thrombosis in cancer patients with venous access devices--prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost. 75:(2)251–253.PubMedGoogle Scholar
  110. 109.
    Karthaus M, Kretzschmar A, Kroning H. et al. 2006; Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol. 17:(2)289–296.PubMedGoogle Scholar
  111. 110.
    Verso M, Agnelli G, Bertoglio S. et al. 2005; Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol. 23:(18)4057–4062.PubMedGoogle Scholar
  112. 111.
    Wells PS. 2005; The role of qualitative D-dimer assays, clinical probability, and noninvasive imaging tests for the diagnosis of deep vein thrombosis and pulmonary embolism. Semin Vasc Med. 5:(4)340–350.PubMedGoogle Scholar
  113. 112.
    Oudega R, Hoes AW, Moons KG. 2005; The Wells rule does not adequately rule out deep venous thrombosis in primary care patients. Ann Intern Med. 143:(2)100–107.PubMedGoogle Scholar
  114. 113.
    Lee AY, Julian JA, Levine MN. et al. 1999; Clinical utility of a rapid whole-blood D-dimer assay in patients with cancer who present with suspected acute deep venous thrombosis. Ann Intern Med. 131:(6)417–423.PubMedGoogle Scholar
  115. 114.
    Sohne M, Kruip MJ, Nijkeuter M. et al. 2006; Accuracy of clinical decision rule, D-dimer and spiral computed tomography in patients with malignancy, previous venous thromboembolism, COPD or heart failure and in older patients with suspected pulmonary embolism. J Thromb Haemost. 4:(5)1042–1046.PubMedGoogle Scholar
  116. 115.
    Buller HR, Agnelli G, Hull RD. et al. 2004; Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 126:(3 Suppl)401S–428S.PubMedGoogle Scholar
  117. 116.
    Segal JB, Bolger DT, Jenckes MW. et al. 2003; Outpatient therapy with low molecular weight heparin for the treatment of venous thromboembolism: a review of efficacy, safety, and costs. Am J Med. 115:(4)298–308.PubMedGoogle Scholar
  118. 117.
    Warkentin TE, Greinacher A. 2004; Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 126:(3 Suppl)311S–337S.PubMedGoogle Scholar
  119. 118.
    Kearon C, Ginsberg JS, Julian JA. et al. 2006; Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA. 296:(8)935–942.PubMedGoogle Scholar
  120. 119.
    Martel N, Lee J, Wells PS. 2005; Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 106:(8)2710–2715.PubMedGoogle Scholar
  121. 120.
    Kuo KH, Kovacs MJ. 2005; Fondaparinux: a potential new therapy for HIT. Hematology. 10:(4)271–275.PubMedGoogle Scholar
  122. 120a.
    Warkentin TE, Maurer BT, Aster RH. Heparin-Induced Thrombocytopenia Associated with Fondaparinux. New Eng J Med. 2007;356(25):2653–2655.PubMedGoogle Scholar
  123. 121.
    Merli G, Spiro TE, Olsson CG. et al. 2001; Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med. 134:(3)191–202.PubMedGoogle Scholar
  124. 122.
    Crowther MA, Berry LR, Monagle PT, Chan AK. 2002; Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol. 116:(1)178–186.PubMedGoogle Scholar
  125. 123.
    Bijsterveld NR, Moons AH, Boekholdt SM. et al. 2002; Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation. 106:(20)2550–2554.PubMedGoogle Scholar
  126. 124.
    Ageno W, Grimwood R, Limbiati S. et al. 2005; Home-treatment of deep vein thrombosis in patients with cancer. Haematologica. 90:(2)220–224.PubMedGoogle Scholar
  127. 125.
    Siragusa S, Arcara C, Malato A. et al. 2005; Home therapy for deep vein thrombosis and pulmonary embolism in cancer patients. Ann Oncol. 16:(Suppl 4)iv136–iv139.PubMedGoogle Scholar
  128. 126.
    Dager WE, King JH, Branch JM. et al. 2005; Tinzaparin in outpatients with pulmonary embolism or deep vein thrombosis. Ann Pharmacother. 39:(7–8)1182–1187.PubMedGoogle Scholar
  129. 127.
    Kovacs MJ, Anderson D, Morrow B. et al. 2000; Outpatient treatment of pulmonary embolism with dalteparin. Thromb Haemost. 83:(2)209–211.PubMedGoogle Scholar
  130. 128.
    Goldhaber SZ, Visani L, De Rosa M. 1999; Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 353:(9162)1386–1389.PubMedGoogle Scholar
  131. 129.
    Wicki J, Perrier A, Perneger TV. et al. 2000; Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thromb Haemost. 84:(4)548–552.PubMedGoogle Scholar
  132. 130.
    Kucher N, Rossi E, De Rosa M, Goldhaber SZ. 2005; Prognostic role of echocardiography among patients with acute pulmonary embolism and a systolic arterial pressure of 90 mmHg or higher. Arch Intern Med. 165:(15)1777–1781.PubMedGoogle Scholar
  133. 131.
    Schoepf UJ, Kucher N, Kipfmueller F. et al. 2004; Right ventricular enlargement on chest computed tomography: a predictor of early death in acute pulmonary embolism. Circulation. 110:(20)3276–3280.PubMedGoogle Scholar
  134. 132.
    O’Connell CL, Boswell WD, Duddalwar V. et al. 2006; Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance. J Clin Oncol. 24:(30)4928–4932.PubMedGoogle Scholar
  135. 133.
    Konstantinides S, Geibel A, Heusel G. et al. 2002; Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med. 347:(15)1143–1150.PubMedGoogle Scholar
  136. 134.
    Comerota AJ, Aldridge SC. 1993; Thrombolytic therapy for deep venous thrombosis: a clinical review. Can J Surg. 36:(4)359–364.PubMedGoogle Scholar
  137. 135.
    Mewissen MW, Seabrook GR, Meissner MH. et al. 1999; Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry. Radiology. 211:(1)39–49.PubMedGoogle Scholar
  138. 136.
    Kim HS, Patra A, Paxton BE. et al. 2006; Adjunctive percutaneous mechanical thrombectomy for lower-extremity deep vein thrombosis: clinical and economic outcomes. J Vasc Interv Radiol. 17:(7)1099–1104.PubMedGoogle Scholar
  139. 137.
    Hann CL, Streiff MB. 2005; The role of vena caval filters in the management of venous thromboembolism. Blood Rev. 19:(4)179–202.PubMedGoogle Scholar
  140. 138.
    Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation. 2005; 112:(3)416–422.Google Scholar
  141. 139.
    Linenberger ML. 2006; Catheter-related thrombosis: risks, diagnosis, and management. J Natl Compr Canc Netw. 4:(9)889–901.PubMedGoogle Scholar
  142. 140.
    Streiff MB. 2006; Long-term therapy of venous thromboembolism in cancer patients. J Natl Compr Canc Netw. 4:(9)903–910.PubMedGoogle Scholar
  143. 141.
    Ansell J, Hirsh J, Poller L. et al. 2004; The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 126:(3 Suppl)204S–233S.PubMedGoogle Scholar
  144. 142.
    Streiff MB, Segal JB, Tamariz LJ. et al. 2006; Duration of vitamin K antagonist therapy for venous thromboembolism: a systematic review of the literature. Am J Hematol. 81:(9)684–691.PubMedGoogle Scholar
  145. 143.
    Palareti G, Legnani C, Lee A. et al. 2000; A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost. 84:(5)805–810.PubMedGoogle Scholar
  146. 144.
    Prandoni P, Lensing AW, Piccioli A. et al. 2002; Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 100:(10)3484–3488.PubMedGoogle Scholar
  147. 145.
    Hutten BA, Prins MH, Gent M. et al. 2000; Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol. 18:(17)3078–3083.PubMedGoogle Scholar
  148. 146.
    Meyer G, Marjanovic Z, Valcke J. et al. 2002; Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 162:(15)1729–1735.PubMedGoogle Scholar
  149. 147.
    Deitcher SR, Kessler CM, Merli G. et al. 2006; Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost. 12:(4)389–396.PubMedGoogle Scholar
  150. 148.
    Hull RD, Pineo GF, Brant RF,. et al. 2006; Long-term low molecular weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med119:(12)1062–1072.PubMedGoogle Scholar
  151. 149.
    Lee AY, Levine MN, Baker RI. et al. 2003; Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 349:(2)146–153.PubMedGoogle Scholar
  152. 150.
    Aujesky D, Smith KJ, Cornuz J, Roberts MS. 2005; Cost-effectiveness of low-molecular-weight heparin for secondary prophylaxis of cancer-related venous thromboembolism. Thromb Haemost. 93:(3)592–599.PubMedGoogle Scholar
  153. 151.
    Bernardi E, Bagatella P, Frulla M. et al. 2001; Postthrombotic syndrome: incidence, prevention, and management. Semin Vasc Med. 1:(1)71–80.PubMedGoogle Scholar
  154. 152.
    Prandoni P, Villalta S, Bagatella P. et al. 1997; The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica. 82:(4)423–428.PubMedGoogle Scholar
  155. 153.
    Prandoni P, Lensing AW, Prins MH. et al. 2004; Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med. 141:(4)249–256.PubMedGoogle Scholar
  156. 154.
    Brandjes DP, Buller HR, Heijboer H. et al. 1997; Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet. 349:(9054)759–762.PubMedGoogle Scholar
  157. 155.
    Crowther MA, Ginsberg JS, Julian J. et al. 2003; A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 349:(12)1133–1138.PubMedGoogle Scholar
  158. 156.
    Luk C, Wells PS, Anderson D, Kovacs MJ. 2001; Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy. Am J Med. 111:(4)270–273.PubMedGoogle Scholar
  159. 157.
    Warkentin TE, Greinacher A. 2004; Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 126:(3 Suppl)311S–337S.PubMedGoogle Scholar
  160. 158.
    Sack GH, Jr., Levin J, Bell WR. 1977; Trousseau’s syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore). 56:(1)1–37.Google Scholar
  161. 159.
    Merli G, Spiro TE, Olsson CG. et al. 2001; Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med. 134:(3)191–202.PubMedGoogle Scholar
  162. 160.
    Zacharski LR, Henderson WG, Rickles FR. et al. 1984; Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer. 53:(10)2046–2052.PubMedGoogle Scholar
  163. 161.
    Aisner J, Goutsou M, Maurer LH. et al. 1992; Intensive combination chemotherapy, concurrent chest irradiation, and warfarin for the treatment of limited-disease small-cell lung cancer: a Cancer and Leukemia Group B pilot study. J Clin Oncol. 10:(8)1230–1236.PubMedGoogle Scholar
  164. 162.
    Maurer LH, Herndon JE, Hollis DR. et al. 1997; Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. J Clin Oncol. 15:(11)3378–3387.PubMedGoogle Scholar
  165. 163.
    Chahinian AP, Propert KJ, Ware JH. et al. 1989; A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol. 7:(8)993–1002.PubMedGoogle Scholar
  166. 164.
    Smorenburg SM, Van Noorden CJ. 2001; The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev. 53:(1)93–105.PubMedGoogle Scholar
  167. 165.
    Dolovich LR, Ginsberg JS, Douketis JD. et al. 2000; A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med. 160:(2)181–188.PubMedGoogle Scholar
  168. 166.
    Kakkar AK, Levine MN, Kadziola Z. et al. 2004; Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. 22:(10)1944–1948.PubMedGoogle Scholar
  169. 167.
    Klerk CP, Smorenburg SM, Otten HM. et al. 2005; The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 23:(10)2130–2135.PubMedGoogle Scholar
  170. 168.
    Lee AY, Rickles FR, Julian JA. et al. 2005; Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 23:(10)2123–2129.PubMedGoogle Scholar
  171. 169.
    Altinbas M, Coskun HS, Er O. et al. 2004; A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost. 2:(8)1266–1271.PubMedGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science + Business Media, LLC 2009

Authors and Affiliations

  1. 1.Division of Hematology, Sidney Kimmel Comprehensive Cancer CenterJohns Hopkins Medical InstitutionsBaltimoreUSA

Personalised recommendations